Federal Trade Commission v. AbbVie Inc. et al.

Date Filed: September 8, 2014
Status: Decided
District Court: Eastern District of Pennsylvania – 2:14-cv-05151-HB
Nature of Suit: Generic Competition Block or Delay|Antitrust
Defendant Type: Pharma
Plaintiff Type: Federal
Case Info: https://www.ftc.gov/enforcement/cases-proceedings/121-0028/abbvie-inc-et-al
Court Document: http://freepdfhosting.com/f986e77a4e.pdf

FTC alleged AbbVie sued generic companies for patent infringement over their proposed generic version of the testosterone gel, AndroGel, without justifiable grounds but merely to delay the generics. A federal judge in Philadelphia found that AbbVie illegally delayed generic versions of its testosterone replacement drug AndroGel from entering the market and ordered the payment of $448 million in illegal profits to consumers.

Associated Legislation:

No items found